Literature DB >> 809835

Co-trimoxazole compared to chloramphenicol in the treatment of enteric fever.

M Uwaydah, R Matossian, M Balabanian.   

Abstract

Co-trimoxazole (trimethoprim-sulphamethoxazole combination) was effective in the control of the acute infection in 60 patients with proven enteric fever. The mean interval between initiating treatment and defervescence was similar to that observed with a comparable group of 38 patients treated with chloramphenicol. Both co-trimoxazole and chloramphenicol were well tolerated and no serious adverse reactions, attributed to either drug, were noted. Two patients treated with chloramphenicol relapsed. No relapses were noted in the co-trimoxazole treated group. Although the evidence available at present in inadequate for drawing final conclusions regarding the relative efficacy of these two therapeutic agents in enteric fever, co-trimoxazole should be considered as an alternative drug, particularly when encountering salmonella strains resistant to chloramphenicol and ampicillin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 809835     DOI: 10.3109/inf.1975.7.issue-2.08

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  Therapy of antimicrobial-resistant typhoid fever.

Authors:  T Butler; N N Linh; K Arnold; M D Adickman; D M Chau; M M Muoi
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

2.  Cefazolin in the treatment of acute enteric fever.

Authors:  M Uwaydah
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

Review 3.  Chemotherapy of typhoid fever: a review of literature.

Authors:  C Herzog
Journal:  Infection       Date:  1976       Impact factor: 3.553

4.  The combination of pivmecillinam and pivampicillin compared to co-trimoxazole in the treatment of enteric fever.

Authors:  D Tanphaichitra; A Bussayanond; O Christensen
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 5.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.